Early Treatment With Olmesartan Prevents Juxtamedullary Glomerular Podocyte Injury and the Onset of Microalbuminuria in Type 2 Diabetic Rats

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

(2011) Hermann Haller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aliskiren Inhibits Intracellular Angiotensin II Levels Without Affecting (Pro)renin Receptor Signals in Human Podocytes

(2010) M. Sakoda et al.   AMERICAN JOURNAL OF HYPERTENSION

Angiotensin II receptor blocker is a renoprotective remedy for metabolic syndrome

(2009) Tadashi Sofue et al.   HYPERTENSION RESEARCH

Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model

(2009) Mizuki Mizukawa et al.   HYPERTENSION RESEARCH

Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria

(2009) Akira Nishiyama et al.   JOURNAL OF HYPERTENSION

Mineralocorticoid Receptor Blockade Enhances the Antiproteinuric Effect of an Angiotensin II Blocker through Inhibiting Podocyte Injury in Type 2 Diabetic Rats

(2009) A. Nishiyama et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS